The healthcare giant raised its outlook for the year, yet the market is holding back its reward, creating a tense waiting ...

Politicians serve on committees that set healthcare policy, monitor government contracts, and shape regulatory frameworks.

The healthcare giant is making waves, but its true value for investors lies in how little it moves with the market.

Johnson & Johnson stock makes good drugs, but it's valuation isn't great.

Johnson & Johnson offers a unique blend of steady growth, portfolio depth, and resilience. Click here to read why I rate JNJ ...

I keep hitting the buy button on Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) because I have stopped trying to find a ...

Johnson & Johnson ( JNJ) snapped six straight sessions of gains on Tuesday as its shares lost 1.76% to settle at $253.97. The fall came amid a wider decline in the healthcare sector. Other healthcare ...

Johnson & Johnson (NYSE:JNJ) has rallied 13.73% year to date and 55.27% over the past year, fueled by oncology blockbusters and a MedTech franchise hitting on every cylinder. CEO Joaquin Duato told ...

Eli Lilly (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ) just reported Q1 2026 results that read like two different playbooks ...

Bristol Myers Squibb leans on specialty medicines and a discounted valuation, while Johnson & Johnson boasts industry-leading ...